TR2022000350A2 - Inhalation Product Containing Eucalyptus - Google Patents
Inhalation Product Containing EucalyptusInfo
- Publication number
- TR2022000350A2 TR2022000350A2 TR2022/000350 TR2022000350A2 TR 2022000350 A2 TR2022000350 A2 TR 2022000350A2 TR 2022/000350 TR2022/000350 TR 2022/000350 TR 2022000350 A2 TR2022000350 A2 TR 2022000350A2
- Authority
- TR
- Turkey
- Prior art keywords
- oil
- essential oil
- inhalation
- eucalyptus
- product containing
- Prior art date
Links
- 244000166124 Eucalyptus globulus Species 0.000 title claims abstract 4
- 239000000341 volatile oil Substances 0.000 claims abstract description 23
- 235000002020 sage Nutrition 0.000 claims abstract description 10
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 2
- 235000019506 cigar Nutrition 0.000 claims 1
- 239000000295 fuel oil Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 abstract description 2
- 229940127555 combination product Drugs 0.000 abstract description 2
- 239000001342 boswellia carteri birdw. oil Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000219927 Eucalyptus Species 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000003443 antiviral agent Substances 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 150000002936 p-menthane-3,8-diol derivatives Chemical class 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Abstract
SARS Cov-2 enfeksiyonlarının önlenmesinde ve tedavisinde kullanılabilecek, ökaliptus uçucu yağı, adaçayı uçucu yağı ve sığala yağını içeren kombinasyon ürününü açıklamaktadır.It describes a combination product containing eucalyptus essential oil, sage essential oil, and frankincense oil that can be used in the prevention and treatment of SARS Cov-2 infections.
Description
TARIFNAME Ökaliptus Uçucu Yagi Içeren Inhalasyon Ürünü Teknik Alan Bu bulus inhalasyon yoluyla hastalara verilmek üzere gelistirilmis ökaliptus uçucu yagi, adaçayi uçucu yagi ve sigala yagi içeren kombine ürünler hakkindadir. Önceki Teknik Su anda COVlD-19'a neden olan koronavirüs olan SARS-CoV-Z'yi tedavi etmek için çesitli antiviral ajanlar kullanilmaktadir. Ancak bunlarin bir kisminin hastaya uygulanmasi zorken bir kismininda yan etkileri fazladir. Bu ilaçlari içeren inhalasyon yolu ile verilebilecek kuru toz formülü mevcut degildir. Örnegin, Remdesivir SARS-CoV-2'yi tedavi etmek için genellikle intravenöz uygulama ile iniüzyon halinde verilir. Remdesivir, agir hastalik nedeniyle hastaneye yatirilan yetiskin ve pediatrik hastalarda acil durumlarda kullanilmaktadir. Ilk önceleri Ebola virüsü hastaligini tedavi etmek için gelistirilen remdesivir, insan hava yolu epitel hücrelerinde COVlD-19'u tedavi etmek için umut verici sonuçlar göstermistir. Bununla birlikte, sinirli etkili uygulama yöntemleri, yasami tehdit eden semptomlar sergileyen hastalara yaygin tedavi uygulama çabalarini engellemistir. SARS-CoV-2 virüsünün ilk yerlestigi bölge üst solunum yoludur. Bu nedenle günlük hayatin içinde virüsün yerlesmesini engelleyecek virüsün ilk yerlesim bölgesinde çogalmasini önleyecek formülasyonlara ihtiyaç bulunmaktadir. Bogaz pastilleri bu nedenle sikça tercih edilen ürünler olmakla beraber seker içerikleri nedeni ile bazen kullanimlari tercih edilmemektedir. Antimikrobiyal etkinligi bilinen çok sayida bitki ve bitkisel madde bulunmaktadir. Bunlarin çok farkli kombinasyonlarinin yapilmasi mümkündür. Bu antimikrobiyal ajanlarda daha çok bakteriyel enfeksiyonlar için kombine edilmis olup viral enfeksiyonlar için gelistirilmis ürünlerin sayisi sinirlidir. ekstresini benzalkonyum klorür ile birlikte içeren antiviral kombinasyonlar hakkindadir. içeren ürünler hakkindadir. USZOO4/007l757 numarali patent basvurusu solunum yolu enfeksiyonlarmda intranasal yama kullanilmasi hakkindadir. Bu basvuru kombinasyonda kullanilan bilesiklerden çok uygulama metodu hakkindadir. EP1748769 numarali patent basvurusu daha önce antiseptik antifungal antibakteriyel etkisi gösterilmis p-mentan-3,8-diol bilesiklerinin antiviral olarak kullanilmasi hakkindadir. Bu buluslarin hiçbirisi viral enfeksiyonlarda kullanilacak hizli ve etkili kombinasyonlar ve bunlarin formülasyonlari hakkinda degildir. Yine bu buluslarin hiçbiri SARS COV-2 enfeksiyonlarindan korunma metodu hakkinda degildir. Uygulamasi kolay etkili ve güvenilir antiviral kompozisyonlarinin gelistirilmesine ihtiyaç vardir. Bu bulus SARS CoV-Z viral enfeksiyonlardan korunmada ve viral enfeksiyon tedavisine yardimci, uygulamasi kolay, güvenilir kombinasyonlar ve bu kombinasyonlarin hazirlanma metodu hakkindadir. Bulusun çözümünü amaçladigi teknik problemler Bu bulus ökaliptus uçucu yagi, adaçayi uçucu yagi ve sigala yagini içeren inhalasyon yoluyla hastalara verilmek üzere gelistirilmis inhalasyon ürünleri hakkindadir. Bu bulus COVID-l9 hastalarini tedavi etmek için inhalasyon yoluyla dogrudan akcigerlere verilebilecektir. Bugüne kadar ökaliptus uçucu yagi, adaçayi uçucu yagi ve sigala yagini bir arada içeren ve inhalasyon yoluyla kullanilabilecek bir ürün gelistirilmemistir. COVID-19 hastaligi tedavisi zor bir hastaliktir. COVID-19 hastaliginda yan etkisi çok fazla olan ilaçlarin yerine ökaliptus uçucu yaginin, adaçayi uçucu yaginin ve Sigala yaginin hedef dokulara dogrudan ulasmasini saglayan ürünler ile etkin bir tedavi saglayacaktir. Tedavisi zor olan bu hastalikta uygulama kolayligi olan ürün gelistirilerek hastane yükü ve ölüm risklerini artiran yan etki insidansi azaltilacak ve hastaligin erken dönemde önlenmesi ile çok sayida kisiye bulasmasinin önüne geçilecektir. Ökaliptus uçucu yagi, adaçayi uçucu yagi ve Sigala yagi gerekirse bir baska antiviral ajanla ve/veya antiseptik ajanlarla beraber kullanilabilir. SARS CoV-Z enfeksiyonun tedavisinde ökaliptus uçucu yagi, adaçayi uçucu yagi ve sigala yaginin bir arada ve gerektiginde bir baska antiviral ajanla ve/veya antiseptik a janlarla beraber kullanilmasi, dozlari ve hazirlama teknigi belli degildir, bu bulus bunlari açiklamaktadir. Bulusun Açiklamasi Bu bulus konusu kombinasyon inhalasyon yolu ile verilir. Inhalasyon için bugu yöntemi kullanilabilir, damla olarak kullanilabilir, difuzörler kullanilabilir, vazelin gibi yagli bir vasatta çözüp bas, gögüs veya burun deliklerine uygulanabilir, Difüzörler kullanilmasi özellikle tercih edilir. Antiviral ajan olarak bu bulusta ökaliptus uçucu yagi, adaçayi uçucu yagi ve Sigala yagi kullanilir. Bu uçucu yaglar diger antiviral ajanlarla, antiseptik ajanlarla kombine edilebilir. Kombine edilecek ajanlar arasinda mentol tercih edilebilir. Bu bulustaki kombinasyonda ökaliptus uçucu yaginin %90'dan az olmamasi istenir. Sigala yagi ve ökaliptus uçucu yaginin %10'dan fazla olmamasi, Sigala yaginin da bu karisimda %3 "ten fazla olmasi istenmez. Bulustaki kombinasyonun tercihen Yagi içermesi özellikle tercih edilir. Bu bulus kombinasyonuna ek antiviral veya antiseptik etkisi ile bilinen diger ajanlar katilabilir. Diger ajanlar arasinda bomeol, mentol sayilabilir. Bulusun diger ajanlarla kombinasyonu burada anlatilanlarla sinirli degildir. Bulusun sanayiye uygulanma biçimi Bu bulusta verilen kombinasyon ürünü sanayide rutinde kullanilan cihaz ve ekipman ile çok kolaylikla üretilebilecek bir formüldür. TR TR DESCRIPTION Inhalation Product Containing Eucalyptus Essential Oil Technical Field This invention is about combined products containing eucalyptus essential oil, sage essential oil and sage oil developed to be given to patients via inhalation. Prior Art Various antiviral agents are currently used to treat SARS-CoV-Z, the coronavirus that causes COVID-19. However, some of them are difficult to apply to the patient, while some of them have many side effects. There is no dry powder formula containing these drugs that can be administered by inhalation. For example, Remdesivir is usually given as an infusion by intravenous administration to treat SARS-CoV-2. Remdesivir is used in emergency situations in adult and pediatric patients who are hospitalized due to severe illness. Originally developed to treat Ebola virus disease, remdesivir has shown promising results for treating COVlD-19 in human airway epithelial cells. However, limited effective delivery methods have hindered efforts to apply widespread treatment to patients exhibiting life-threatening symptoms. The first area where the SARS-CoV-2 virus settles is the upper respiratory tract. For this reason, there is a need for formulations that will prevent the virus from settling in daily life and prevent the virus from multiplying in the first settlement area. For this reason, throat lozenges are frequently preferred products, but their use is sometimes not preferred due to their sugar content. There are many plants and herbal substances known to have antimicrobial activity. It is possible to make many different combinations of these. These antimicrobial agents are mostly combined for bacterial infections, and the number of products developed for viral infections is limited. About antiviral combinations containing its extract together with benzalkonium chloride. About products containing . The patent application numbered USZOO4/0071757 is about the use of intranasal patches in respiratory tract infections. This application is about the method of application rather than the compounds used in the combination. The patent application numbered EP1748769 is about the antiviral use of p-menthane-3,8-diol compounds, which have previously been shown to have antiseptic, antifungal and antibacterial effects. None of these inventions are about fast and effective combinations and their formulations to be used in viral infections. Again, none of these inventions are about the method of protection from SARS COV-2 infections. There is a need to develop effective and reliable antiviral compositions that are easy to apply. This invention is about easy-to-apply, reliable combinations that help prevent and treat SARS CoV-Z viral infections and the method of preparation of these combinations. Technical problems that the invention aims to solve. This invention is about inhalation products developed to be given to patients by inhalation, containing eucalyptus essential oil, sage essential oil and sigala oil. This invention can be delivered directly into the lungs via inhalation to treat COVID-19 patients. To date, no product has been developed that contains eucalyptus essential oil, sage essential oil and sigala oil together and can be used by inhalation. COVID-19 disease is a difficult disease to treat. In COVID-19 disease, effective treatment will be provided with products that allow eucalyptus essential oil, sage essential oil and Sigala oil to reach target tissues directly, instead of drugs that have many side effects. By developing a product that is easy to apply in this disease, which is difficult to treat, the incidence of side effects that increase hospital burden and death risks will be reduced, and by preventing the disease in the early stages, its transmission to a large number of people will be prevented. Eucalyptus essential oil, sage essential oil and Sigala oil can be used together with another antiviral agent and/or antiseptic agents if necessary. The use of eucalyptus essential oil, sage essential oil and calendula oil together and when necessary with another antiviral agent and/or antiseptic agents in the treatment of SARS CoV-Z infection, their dosage and preparation technique are not clear, but this invention explains these. Description of the invention The combination of this invention is given by inhalation. Mist method can be used for inhalation, it can be used as drops, diffusers can be used, it can be dissolved in an oily medium such as vaseline and applied to the head, chest or nostrils. Using diffusers is especially preferred. Eucalyptus essential oil, sage essential oil and Sigala oil are used as antiviral agents in this invention. These essential oils can be combined with other antiviral agents, antiseptic agents. Among the agents to be combined, menthol may be preferred. In the combination of this invention, it is desired that the eucalyptus essential oil should not be less than 90%. Sigala oil and eucalyptus essential oil should not be more than 10%, and Sigala oil should not be more than 3% in this mixture. It is particularly preferred that the combination in the invention preferably includes Oil. Other agents known for their antiviral or antiseptic effects may be added to this invention combination. Other Among the agents are bomeol and menthol. The combination of the invention with other agents is not limited to what is explained here. The industrial application of the invention. The combination product given in this invention is a formula that can be easily produced with the devices and equipment routinely used in industry.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR2022000350A2 true TR2022000350A2 (en) | 2023-07-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | N-acetylcysteine to combat COVID-19: an evidence review | |
| CN108040468B (en) | Preparation for treating oral cavity, throat and respiratory diseases | |
| Eddleston | The pathophysiology of organophosphorus pesticide self-poisoning is not so simple | |
| Lim et al. | Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review | |
| WO2007080546A2 (en) | Compositions and methods useful for treatment of respiratory illness | |
| WO2021198940A1 (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| TR2022000350A2 (en) | Inhalation Product Containing Eucalyptus | |
| Agrawaal et al. | Clinico-epidemiological study on pesticide poisoning in a tertiary care hospital in Eastern Nepal. | |
| RU2010120806A (en) | MONTELUKAST ACID INHALATION COMPOSITIONS AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | |
| A Marathe et al. | Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases | |
| SULZBERGER et al. | DEVELOPMENT AND USE OF BAL: A Review, with Particular Reference to Arsenical Dermatitis | |
| TR202022087A2 (en) | Inhalation Powder for SARS Cov-2 Infections | |
| RU2790837C2 (en) | Spray for treatment of infected and uninfected wounds in type i diabetes mellitus | |
| FW | The extended therapeutic role of dithiocarb (sodium diethyldithiocarbamate) from nickel poisoning to AIDS | |
| JP2002030000A (en) | Fundamental treatment for common cold | |
| Derry | Iodine: the forgotten weapon against influenza viruses | |
| Orcina et al. | PHTALOX® Mouthwash as An Option to Reduce Clinical Symptoms of COVID-19: Case Series | |
| Schrickel et al. | Recovery from ultra-high dose organophosphate poisoning after “in-the-field” antidote treatment: Potential lessons for civil defense | |
| Gottardi et al. | Thoughts and Questions Arising upon the Recognition of the broadly bioactive and very well tolerated Antiseptic N-Chlorotaureine as a highly useful medicant for prophylaxis and therapy, Herald of the international Academy of Science (Russian Section) | |
| DESAI et al. | Hydroxychloroquine-A Saviour from The Past-A Review | |
| NL1024714C1 (en) | Pharmaceutical composition in the form of a throat spray, useful for treating allergies, comprises a zinc salt and xylitol | |
| Pedersen et al. | Effect of prophylactic treatment with ASAP-AGX-32 and ASAP solutions on an avian influenza a (H5N1) virus infection in mice | |
| CN115916204A (en) | Methods for treating RNA viral infections including COVID-19 (SARS-CoV-2) | |
| CN115919825A (en) | Medicament using oil-soluble formic acid as antiviral and antibacterial raw material and preparation method thereof | |
| AU2008241370B2 (en) | Essential oil of kunzea ambigua and methods of use |